“We delivered outstanding performance in the second quarter, reflecting the strength of our proven growth strategy, our team’s excellent execution and the power of our PPI Business System,” said Marc N. Casper, chairman and ... Read more
The recent Bundibugyo Ebola virus outbreak underscored the limitations of relying solely on highly targeted diagnostics, highlighting the need for more adaptable approaches to infectious disease surveillance. In this interview with BioPharma BoardRoo... Read more
In H1 2026, Lonza1 delivered sales of CHF 3.4 billion with +16.0% CER2 sales growth The CORE EBITDA margin significantly expanded by +4.4ppts versus H1 2025, reaching 34.8% with a CORE EBITDA of CHF 1.2 billion Free Cash Flow (FCF)... Read more
Danaher Corporation announced results for the second quarter 2026. All results in this release reflect only continuing operations and period-to-period comparisons are year-over-year unless otherwise noted. Key Second Quarter 2026 Results ... Read more
Senior secured term loan of up to CHF 250 million with a 5‑year maturity at a fixed 7% interest rate First tranche will fully refinance the existing New Money Facility, maturing in May 2027 Eliminates near‑term debt maturities and strengthens b... Read more
Q1 2026 Group performance Comparable order intake growth 6% Group sales of EUR 3.9 billion, reflecting 4% increase in comparable sales Income from operations increased to EUR 241 million Adjusted EBITA margin increased 40 basis points t... Read more
Samsung Biologics to launch an all-cash public tender offer for 100% of PolyPeptide's fully diluted share capital (excluding therefrom any treasury shares) at CHF 44.31 per share, representing an equity value of approxim... Read more
Consortium initially brings together Lunit, Mindpeak, Imagene AI, Dipath AI, Nucleai, Tivenix and Indica Labs to give biopharma sponsors a single CRO-led, global AI-agnostic path to evaluate and apply digital pathology, image analysis, spatial biol... Read more
© 2026 Biopharma Boardroom. All Rights Reserved.
